Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 8/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.31 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764657 | 0.85 | NPC1 (0.38) | PYGLMEN1KMT2APOLB | |
| SCHEMBL6762557 | 0.84 | ALOX15 (0.42) | PYGLMEN1KMT2APOLBCYP2C9 | |
| SCHEMBL6771442 | 0.83 | CTSL (0.39) | — | |
| SCHEMBL6850218 | 0.82 | PYGL (0.42) | PYGLMEN1KMT2APOLBCYP2C9 | |
| SCHEMBL6846373 | 0.81 | KMT2A (0.41) | MEN1KMT2APOLBSHMT1SHMT2 | |
| SCHEMBL6771023 | 0.79 | TP53 (0.43) | PYGLMEN1KMT2APOLBALOX15 | |
| SCHEMBL8906535 | 0.79 | PYGL (0.34) | PYGLCYP2C9SHMT1SHMT2CXCR5 | |
| SCHEMBL8907090 | 0.77 | GPR132 (0.37) | PYGLCYP2C9SHMT1SHMT2 | |
| SCHEMBL6765927 | 0.76 | ALDH1A1 (0.48) | KMT2APOLB | |
| SCHEMBL6764676 | 0.76 | SHMT1 (0.46) | MEN1KMT2ASHMT1SHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774133-B2 | Substituted spiroheterocyclic 1H-3-aryl-pyrrolidine-2,4-dione derivatives, processes for their preparation, and their use as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2004-08-10 | — | — | US | disclosed |
| US-20040009999-A1 | Substituted spiroheterocyclic 1H-3-aryl-pyrrolidine-2,4-dione derivatives, processes for their preparation, and their use as pesticides | FISCHER REINER (DE) | 2004-01-15 | — | — | US | disclosed |
| US-6555567-B1 | 2-oxo-3-aryl-4-hydroxy-1-aza-8-thiaspiro(4.5)decane derivatives of given formula; use as arthropodicide or nematicide | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-29 | — | — | US | disclosed |
| US-6479489-B1 | AN ARTHROPODICIDAL OR NEMATICIDAL COMPOSITION | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-12 | — | — | US | disclosed |
| US-5981567-A | ARTHROPODICIDAL OR NEMATICIDAL COMPOSITION | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |
| EP-0706527-A1 | SUBSTITUTED SPIROHETEROCYCLIC 1H-3-ARYLPYRROLIDINE-2,4-DIONE DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS PEST-CONTROL AGENTS | BAYER AG (DE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995001358-A1 | SUBSTITUTED SPIROHETEROCYCLIC 1H-3-ARYLPYRROLIDINE-2,4-DIONE DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS PEST-CONTROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009999-A1 | Substituted spiroheterocyclic 1H-3-aryl-pyrrolidine-2,4-dione derivatives, processes for their preparation, and their use as pesticides | DDT, HPD, CAT | PYGL 3807/4885MEN1 2795/4885KMT2A 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.